Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primates.

Publication date: Jul 01, 2025

Long-term adverse consequences of SARS-CoV-2 infection, termed “long COVID” or post-acute sequelae of COVID (PASC), are a major component of overall COVID-19 disease burden. Prior obesity and metabolic disease increase the severity of acute disease, but SARS-CoV-2 infection also contributes to the development of new-onset metabolic disease. Since the COVID pandemic occurred in the context of the global obesity epidemic, an important question is the extent to which pre-existing obesity modifies long-term responses to SARS-CoV-2 infection. We utilized a nonhuman primate model to compare the effects of infection with the SARS-CoV-2 delta variant in lean and obese/insulin-resistant adult male rhesus macaques over a 6-month time course. While some longitudinal responses to SARS-CoV-2 infection, including overall viral dynamics, SARS-CoV-2-specific IgG induction, cytokine profiles, and tissue persistence of viral RNA, did not appreciably differ between lean and obese animals, other responses, including neutralizing Ab dynamics, lung pathology, body weight, degree of insulin sensitivity, adipocytokine profiles, body temperature, and nighttime activity levels were significantly different in lean versus obese animals. Furthermore, several parameters in lean animals were altered following SARS-CoV-2 infection to resemble those in obese animals. Notably, persistent changes in multiple parameters were present in most animals, suggesting that PASC may be more prevalent than estimated from self-reported symptoms in human studies.

Open Access PDF

Concepts Keywords
Obesity Animals
Pathology Antibodies, Viral
Primates Antibodies, Viral
Viral COVID-19
Cytokines
Cytokines
Disease Models, Animal
Macaca mulatta
Male
Obesity
Post-Acute COVID-19 Syndrome
SARS-CoV-2

Semantics

Type Source Name
disease MESH obesity
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH post-acute sequelae of COVID-19
disease MESH sequelae
disease MESH metabolic disease
disease MESH acute disease
disease MESH infection
disease MESH insulin sensitivity
pathway REACTOME Reproduction
drug DRUGBANK Pumactant
pathway REACTOME Metabolism
disease MESH death
drug DRUGBANK Coenzyme M
disease IDO acute infection
disease MESH chronic condition
disease MESH hypertension
disease IDO blood
disease MESH morbidity
pathway KEGG Insulin resistance
disease MESH cardiovascular disease
disease MESH dyslipidemia
pathway REACTOME Glucose metabolism
disease MESH diabetic ketoacidosis
drug DRUGBANK Dansyllysine
disease MESH inflammation
drug DRUGBANK Leptin
pathway KEGG Viral replication
disease MESH viral shedding
disease MESH pulmonary disease
disease MESH interstitial pneumonia
drug DRUGBANK Cholesterol
disease MESH compensatory hyperinsulinemia
disease MESH delta infection
disease MESH viral load
drug DRUGBANK Dimercaprol
disease MESH Disease Models Animal

Original Article

(Visited 2 times, 1 visits today)